Skip to main content
SpringerLink
Log in

Can We End Melanoma As We Know It? The Role of Early Detection in Defeating Deadly Skin Cancer

  • Chapter
  • First Online:
Practical Manual for Dermatologic and Surgical Melanoma Management

  • 419 Accesses

Abstract

Melanoma remains one of the most dangerous types of skin cancer, accounting for an estimated 7230 deaths in 2019. When melanoma is detected at its earliest stage, simple surgical excision can cure the disease (American Cancer Society, Cancer facts & figures 2019, 2019). To date, total body skin examination (TBSE) is the most powerful screening tool for early detection of melanoma. TBSE is most effective and economical when performed on individuals at high risk for the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society. Cancer facts & figures. 2019.

    Google Scholar 

  2. Noone A, Howlader N, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2015. based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

    Google Scholar 

  3. Losina E, Walensky RP, Geller A, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007;143(1):21–8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. US Preventive Services Task Force. Screening for skin cancer: US preventive services task force recommendation statement. JAMA. 2016;316(4):429–35.

    Article  Google Scholar 

  5. Johnson MM, Leachman SA, Aspinwall LG, et al. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017;4(1):13–37.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040–59.

    Article  PubMed  Google Scholar 

  7. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer. 2005;41(1):28–44.

    Article  PubMed  Google Scholar 

  8. Sturm RA, Duffy DL, Box NF, et al. The role of melanocortin‐1 receptor polymorphism in skin cancer risk phenotypes. Pigment Cell Res. 2003;16(3):266–72.

    Article  CAS  PubMed  Google Scholar 

  9. García‐Borrón JC, Abdel‐Malek Z, Jiménez‐Cervantes C. MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation. Pigment Cell Melanoma Res. 2014;27(5):699–720.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. English D, MacLennan R, Rivers J, Kelly J, Armstrong BJ. Epidemiological studies of melanocytic naevi: protocol for identifying and recording naevi. Lyon, France: International Agency for Research on Cancer; 1990. Report No. 90(002).

    Google Scholar 

  11. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97(20):1507–15.

    Article  CAS  PubMed  Google Scholar 

  12. Lazovich D, Vogel RI, Weinstock MA, Nelson HH, Ahmed RL, Berwick M. Association between indoor tanning and melanoma in younger men and women. JAMA Dermatol. 2016;152(3):268–75.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45–60.

    Article  PubMed  Google Scholar 

  14. Ford D, Bliss JM, Swerdlow AJ, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer. 1995;62(4):377–81.

    Article  CAS  PubMed  Google Scholar 

  15. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. Int J Cancer. 1999;17(10):3245–51.

    CAS  Google Scholar 

  16. Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies. Melanoma Res. 2016;26(2):188–94.

    Article  CAS  PubMed  Google Scholar 

  17. Robbins HA, Clarke CA, Arron ST, et al. Melanoma risk and survival among organ transplant recipients. J Invest Dermatol. 2015;135(11):2657–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Fattouh K, Ducroux E, Decullier E, et al. Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. Transpl Int. 2017;30(11):1172–80.

    Article  PubMed  Google Scholar 

  19. Collins L, Quinn A, Stasko T. Skin cancer and immunosuppression. Dermatol Clin. 2019;37(1):83–94.

    Article  CAS  PubMed  Google Scholar 

  20. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol. 2010;146(3):265–72.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869–71.

    Article  CAS  PubMed  Google Scholar 

  22. Moore MM, Geller AC, Warton EM, Schwalbe J, Asgari MM. Multiple primary melanomas among 16,570 patients with melanoma diagnosed at Kaiser Permanente Northern California, 1996 to 2011. J Am Acad Dermatol. 2015;73(4):630–6.

    Article  PubMed  Google Scholar 

  23. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): melanoma. Version 3.2018. July 12, 2018.

    Google Scholar 

  24. Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre-and post-HAART eras: a systematic review and meta-analysis of cohort studies. PLoS One. 2014;9(4):e95096.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Yeung H, Balakrishnan V, Luk KMH, Chen SC. Risk of skin cancers in older persons living with HIV: a systematic review. J Assoc Nurses AIDS Care. 2019;30(1):80–6.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yanik EL, Hernández-Ramírez RU, Qin L, et al. Brief report: cutaneous melanoma risk among people with HIV in the United States and Canada. J Acquir Immune Defic Syndr. 2018;78(5):499–504.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Omland SH, Ahlström MG, Gerstoft J, et al. Risk of skin cancer in patients with HIV: a Danish nationwide cohort study. J Am Acad Dermatol. 2018;79(4):689–95.

    Article  PubMed  Google Scholar 

  28. Olsen CM, Hyrich KL, Knight LL, Green AC. Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis. Melanoma Res. 2016;26(5):517–23.

    Article  CAS  PubMed  Google Scholar 

  29. Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–91.

    Article  PubMed  Google Scholar 

  30. Chen Y, Friedman M, Liu G, Deodhar A, Chu C-Q. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78–88.

    Article  CAS  PubMed  Google Scholar 

  31. Ruas M, Peters G. The p16/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta. 1998;1378:115–77.

    Google Scholar 

  32. Cannon-Albright LA, Goldgar DE, Neuhausen S, et al. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics. 1994;23(1):265–8.

    Article  CAS  PubMed  Google Scholar 

  33. Cannon-Albright LA, Meyer LJ, Goldgar DE, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res. 1994;54(23):6041–4.

    CAS  PubMed  Google Scholar 

  34. Sviderskaya EV, Gray-Schopfer VC, Hill SP, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst. 2003;95(10):723–32.

    Article  CAS  PubMed  Google Scholar 

  35. Bishop JAN, Wachsmuth RC, Harland M, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol. 2000;114(1):28–33.

    Article  CAS  PubMed  Google Scholar 

  36. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94(12):894–903.

    Article  CAS  PubMed  Google Scholar 

  37. Fargnoli MC, Gandini S, Peris K, Maisonneuve P, Raimondi S. MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer. 2010;46(8):1413–20.

    Article  CAS  PubMed  Google Scholar 

  38. Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet. 2014;46(5):482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. O’shea SJ, Robles-Espinoza CD, McLellan L, et al. A population-based analysis of germline BAP1 mutations in melanoma. Hum Mol Genet. 2017;26(4):717–28.

    PubMed  PubMed Central  Google Scholar 

  41. Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet. 2014;46(5):478.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480(7375):94.

    Article  CAS  PubMed  Google Scholar 

  44. Potrony M, Badenas C, Aguilera P, et al. Update in genetic susceptibility in melanoma. Ann Transl Med. 2015;3(15):210.

    PubMed  PubMed Central  Google Scholar 

  45. Ransohoff KJ, Jaju PD, Tang JY, Carbone M, Leachman S, Sarin KY. Familial skin cancer syndromes: increased melanoma risk. J Am Acad Dermatol. 2016;74(3):423–34.

    Article  PubMed  Google Scholar 

  46. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009;61(4):677. e671–677, e614.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev. 2017;36(1):77–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ribero S, Longo C, Glass D, Nathan P, Bataille VJD. What is new in melanoma genetics and treatment? Dermatology. 2016;232(3):259–64.

    Article  CAS  PubMed  Google Scholar 

  49. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.

    Article  Google Scholar 

  50. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50(4):255–63.

    Article  CAS  PubMed  Google Scholar 

  51. Leachman SA, Cassidy PB, Chen SC, et al. Methods of melanoma detection. In: Melanoma. Cham: Springer; 2016. p. 51–105.

    Chapter  Google Scholar 

  52. American Academy of Dermatology. Learning module: the skin exam.

    Google Scholar 

  53. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin. 1985;35(3):130–51.

    Article  CAS  PubMed  Google Scholar 

  54. Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771–6.

    Article  CAS  PubMed  Google Scholar 

  55. Grob J, Bonerandi JJ. The ‘ugly duckling’ sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol. 1998;134(1):103–4.

    Article  CAS  PubMed  Google Scholar 

  56. Cuéllar F, Puig S, Kolm I, et al. Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers. Br J Dermatol. 2009;160(1):48–53.

    Article  PubMed  CAS  Google Scholar 

  57. Zalaudek I, Meiklejohn W, Argenzanio G, Thurber AE, Sturm RA. “White” nevi and “red” melanomas: association with the RHC phenotype of the MC1R gene. J Invest Dermatol. 2009;129(5):1305–7.

    Article  CAS  PubMed  Google Scholar 

  58. Wee E, Wolfe R, Mclean C, Kelly JW, Pan Y. Clinically amelanotic or hypomelanotic melanoma: anatomic distribution, risk factors, and survival. J Am Acad Dermatol. 2018;79(4):645–51. e644.

    Article  PubMed  Google Scholar 

  59. Klebanov N, Gunasekera NS, Lin WM, et al. Clinical spectrum of cutaneous melanoma morphology. J Am Acad Dermatol. 2019;80(1):178–88. e173.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Oregon Health & Science University, Portland, OR, USA

    Elizabeth G. Berry, Olivia M. Lucero & Sancy A. Leachman

Authors
  1. Elizabeth G. Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivia M. Lucero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sancy A. Leachman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth G. Berry .

Editor information

Editors and Affiliations

  1. Division of Dermatology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA

    Delphine J. Lee

  2. Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, CA, USA

    Mark B. Faries

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Berry, E.G., Lucero, O.M., Leachman, S.A. (2021). Can We End Melanoma As We Know It? The Role of Early Detection in Defeating Deadly Skin Cancer. In: Lee, D., Faries, M. (eds) Practical Manual for Dermatologic and Surgical Melanoma Management. Springer, Cham. https://doi.org/10.1007/978-3-030-27400-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27400-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27399-6

  • Online ISBN: 978-3-030-27400-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation